Early discontinuation of empirical antibiotic treatment in neutropenic patients with acute myeloid leukaemia and high-risk myelodysplastic syndrome

ConclusionThe introduction of a protocol promoting restrictive use of EAT resulted in reduction of carbapenem and vancomycin use and appears to be safe in AML or high-risk MDS patients with febrile neutropenia during chemotherapy or SCT.

http://link.springer.com/10.1186/s13756-020-00729-2

Source: Antimicrobial Resistance and Infection Control - May 26, 2020 Category: Infectious Diseases Source Type: research